Treatment-resistant depression sounds straightforward, but in practice the phrase gets overused. A patient is not necessarily treatment resistant just because they still feel depressed after one or two medication trials. The more useful question is whether those treatments were actually adequate in dose, duration, adherence, and diagnostic fit.

Before using the label, it helps to slow down and ask what may be missing from the formulation. Was the diagnosis correct? Was bipolar depression ruled out? Were substances, sleep disorders, psychotic symptoms, trauma, medical contributors, or severe psychosocial stressors part of the picture? Apparent nonresponse often becomes more understandable once the frame widens.

The next step is to review treatment quality, not just treatment count. Some patients stop early because of side effects, some never reach a therapeutic dose, and some were prescribed medications that did not really match the clinical subtype. Calling that resistance can make the problem sound more biologic and fixed than it actually is.

Once the workup is solid and the trials really were adequate, the conversation becomes more productive. At that point augmentation, medication switches, psychotherapy optimization, interventional treatments, and more structured symptom monitoring all become more relevant. The key is that treatment resistance should describe a carefully reviewed clinical situation, not a vague sense that standard care has been disappointing.